Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Director Sells $300,000.00 in Stock

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Director Kim D. Blickenstaff sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $30.00, for a total value of $300,000.00. Following the transaction, the director now directly owns 195,190 shares in the company, valued at $5,855,700. This trade represents a 4.87 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Tandem Diabetes Care Stock Performance

TNDM opened at $30.81 on Monday. The stock has a fifty day moving average of $36.16 and a 200-day moving average of $41.24. Tandem Diabetes Care, Inc. has a fifty-two week low of $18.45 and a fifty-two week high of $53.69. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.08. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The business had revenue of $243.97 million during the quarter, compared to analysts’ expectations of $224.14 million. During the same quarter in the previous year, the company earned ($0.38) EPS. The business’s revenue was up 31.4% on a year-over-year basis. On average, research analysts forecast that Tandem Diabetes Care, Inc. will post -1.73 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Royal Bank of Canada initiated coverage on shares of Tandem Diabetes Care in a report on Wednesday, October 2nd. They set an “outperform” rating and a $65.00 target price on the stock. Canaccord Genuity Group assumed coverage on shares of Tandem Diabetes Care in a research note on Thursday, August 8th. They set a “buy” rating and a $57.00 price objective on the stock. Robert W. Baird cut their target price on shares of Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating for the company in a research note on Thursday, November 7th. Canaccord Genuity Group lowered their price target on Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Finally, Sanford C. Bernstein assumed coverage on Tandem Diabetes Care in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $42.00 price objective for the company. Five analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $54.25.

Institutional Investors Weigh In On Tandem Diabetes Care

Several institutional investors have recently made changes to their positions in TNDM. Brooklyn Investment Group bought a new position in Tandem Diabetes Care during the 3rd quarter worth $28,000. Assetmark Inc. acquired a new stake in shares of Tandem Diabetes Care during the 3rd quarter worth $29,000. ORG Wealth Partners LLC bought a new position in shares of Tandem Diabetes Care in the third quarter worth $30,000. ORG Partners LLC acquired a new position in Tandem Diabetes Care in the second quarter valued at about $31,000. Finally, Waldron Private Wealth LLC bought a new stake in Tandem Diabetes Care during the third quarter worth about $50,000.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.